Crossmark

Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication

Crossref DOI link: https://doi.org/10.1186/s12941-018-0281-x

Published Online: 2018-06-28

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tanabe, Hiroki

Yoshino, Keiichi

Ando, Katsuyoshi

Nomura, Yoshiki

Ohta, Katsuhisa

Satoh, Kiichi

Ichiishi, Eiichiro

Ishizuka, Akiei

Otake, Takaaki

Kohgo, Yutaka

Fujiya, Mikihiro

Okumura, Toshikatsu
Clinical Trials ^BETA

Clinical trials referenced in this document:

umin000032351 at UMIN Japan

Documents that mention this clinical trial

Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication
https://doi.org/10.1186/s12941-018-0281-x
Funding

Funding for this research was provided by:

a research grant from International University of Health and Welfare
License Information

Text and Data Mining valid from 2018-06-28

Version of Record valid from 2018-06-28
More Information

Article History

Received: 2 May 2018

Accepted: 21 June 2018

First Online: 28 June 2018

Document is current

Any future updates will be listed below